We have located links that may give you full text access.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Journal of the American Academy of Dermatology 2022 July 10
BACKGROUND: Effective, well-tolerated oral psoriasis treatments are needed.
OBJECTIVE: To compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor (TYK2), versus placebo and apremilast in adults with moderate to severe plaque psoriasis.
METHODS: Participants were randomized 2:1:1 to deucravacitinib 6 mg QD (n=332), placebo (n=166), or apremilast 30 mg BID (n=168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary endpoints included response rates for ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at Week 16.
RESULTS: At Week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < 0.0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < 0.0001). Efficacy improved beyond Week 16 and was maintained through Week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.
LIMITATIONS: One-year duration, limited racial diversity.
CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.
OBJECTIVE: To compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor (TYK2), versus placebo and apremilast in adults with moderate to severe plaque psoriasis.
METHODS: Participants were randomized 2:1:1 to deucravacitinib 6 mg QD (n=332), placebo (n=166), or apremilast 30 mg BID (n=168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary endpoints included response rates for ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at Week 16.
RESULTS: At Week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < 0.0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < 0.0001). Efficacy improved beyond Week 16 and was maintained through Week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.
LIMITATIONS: One-year duration, limited racial diversity.
CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app